Market Cap | 162.33M | P/E | - | EPS this Y | 4.00% | Ern Qtrly Grth | - |
Income | -68.88M | Forward P/E | -2.62 | EPS next Y | 23.10% | 50D Avg Chg | 1.00% |
Sales | 1.68M | PEG | 0.19 | EPS past 5Y | - | 200D Avg Chg | 9.00% |
Dividend | N/A | Price/Book | 1.58 | EPS next 5Y | -1.60% | 52W High Chg | -53.00% |
Recommedations | 3.00 | Quick Ratio | 4.65 | Shares Outstanding | 60.96M | 52W Low Chg | 76.00% |
Insider Own | 0.70% | ROA | -38.10% | Shares Float | 37.64M | Beta | 0.31 |
Inst Own | 88.03% | ROE | -95.93% | Shares Shorted/Prior | 413.79K/223.03K | Price | 3.28 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 191,390 | Target Price | 0.95 |
Oper. Margin | -4,421.81% | Earnings Date | Aug 6 | Volume | 58,772 | Change | 0.00% |
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
HC Wainwright & Co. | Neutral | May 7, 24 |
Jefferies | Hold | May 7, 24 |
BTIG | Neutral | May 6, 24 |
HC Wainwright & Co. | Buy | May 1, 24 |
B of A Securities | Buy | Mar 25, 24 |
HC Wainwright & Co. | Buy | Mar 22, 24 |
HC Wainwright & Co. | Buy | Oct 2, 23 |
B of A Securities | Buy | Sep 12, 23 |
HC Wainwright & Co. | Buy | Aug 31, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Waksal Harlan | Executive Chair Executive Chair | Nov 10 | Buy | 2.9638 | 25,000 | 74,095 | 261,966 | 11/13/23 |
MERRIFIELD C ANN | Director Director | May 13 | Buy | 4.91 | 3,828 | 18,795 | 7,328 | 05/17/22 |
PERCEPTIVE ADVISORS LLC | Director Director | Apr 12 | Buy | 4.22 | 5,924,170 | 24,999,997 | 7,858,285 | 04/14/22 |
Waksal Harlan | Executive Chair Executive Chair | Apr 12 | Buy | 4.22 | 236,966 | 999,997 | 236,966 | 04/13/22 |